| 000 | 01060 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517110715.0 | ||
| 264 | 0 | _c20180312 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1591-9528 | ||
| 024 | 7 |
_a10.1007/s10238-016-0433-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVestita, Michelangelo | |
| 245 | 0 | 0 |
_aVismodegib and risk of cholestatic injury: should we screen candidate patients? _h[electronic resource] |
| 260 |
_bClinical and experimental medicine _c08 2017 |
||
| 300 |
_a415-416 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAnilides |
| 650 | 0 | 4 | _aAntineoplastic Agents |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPyridines |
| 650 | 0 | 4 | _aSkin Neoplasms |
| 700 | 1 | _aLospalluti, Lucia | |
| 700 | 1 | _aGiudice, Giuseppe | |
| 700 | 1 | _aBonamonte, Domenico | |
| 700 | 1 | _aRossiello, Ignazio | |
| 700 | 1 | _aFiloni, Angela | |
| 773 | 0 |
_tClinical and experimental medicine _gvol. 17 _gno. 3 _gp. 415-416 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10238-016-0433-2 _zAvailable from publisher's website |
| 999 |
_c26291895 _d26291895 |
||